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Introduction: Pulmonary toxicities associated with chemotherapeutic agents utilized as adjuvant therapy in
patients with breast cancer are distinctly uncommon. The chemotherapy regimen of docetaxel/cyclophosphamide
has a more favorable therapeutic index compared to anthracycline-based regimens due to a significantly lower
incidence of heart failure and leukemia. Consequently, docetaxel/cyclophosphamide is the preferred adjuvant
chemotherapy of choice in older women or in women where anthracyclines may be contraindicated. Pulmonary
complications in patients with breast cancer receiving taxane-based adjuvant chemotherapy in the absence of
radiation are distinctly uncommon. Here, we report the case of a patient receiving adjuvant docetaxel/
cyclophosphamide who developed rapid-onset, biopsy-proven interstitial pneumonitis.
Case presentation: A 72-year-old Hispanic woman was diagnosed as having stage 3 hormone-receptor positive,
human epidermal growth factor receptor 2/neu negative, invasive breast cancer. Due to the estimated 10-year risk
of recurrence of approximately 80 percent, a decision was made to treat our patient with adjuvant chemotherapy.
Due to her age and increased risk of cardiac toxicity with anthracycline-based chemotherapy regimens, our patient
was treated with docetaxel/cyclophosphamide chemotherapy for a total of four planned cycles. However,
approximately two weeks after receiving the third cycle of chemotherapy, our patient developed rapidly
progressive dyspnea, and a non-productive cough and went to the emergency room at an outside medical facility.
She was found to have mild hypoxemia, and new onset of peripheral, subpleural fibrotic changes not present on
pre-treatment scans. A thorascopic-guided wedge biopsy of the lung tissue revealed subacute interstitial
pneumonitis. Our patient made a rapid clinical recovery after treatment with corticosteroids.
Conclusions: Interstitial pneumonitis is a rare complication of docetaxel/cyclophosphamide chemotherapy that
carries a high mortality rate. The only way to make a definitive diagnosis is with a wedge biopsy of the lung, which
should be performed when feasible. Our patient’s case illustrates that no therapeutic intervention is without its
intrinsic and unanticipated risks, and interstitial pneumonitis should be discussed as a potential side effect with all
patients prior to administering docetaxel/cyclophosphamide chemotherapy.* Correspondence: amontero2@med.miami.edu
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One of the primary disadvantages of most cytotoxic che-
motherapeutic agents is their narrow therapeutic index
due to off target adverse effects [1]. While the most
common chemotherapy-related toxicities are typically
self-limiting, others are much less common, and poten-
tially life threatening. One of the most feared toxicities
of adjuvant chemotherapy in patients with breast cancer
is anthracycline-induced cardiac toxicity, and therapy-
induced leukemia. Lung-related toxicities with che-
motherapeutic agents used in breast cancer are distinctly
uncommon, however they are well known with drugs
used in other solid tumors, for example, bleomycin and
methotrexate [2].
Docetaxel/cyclophosphamide (TC) has been shown in
a prospective randomized trial to be superior to doxo-
rubicin/cyclophosphamide (AC) in improving overall
and disease-free survival in patients with breast cancer,
with a more favorable therapeutic index due to a signifi-
cantly lower incidence of heart failure and leukemia [3].
TC is consequently the preferred adjuvant chemotherapy
of choice in women with lymph-node negative breast
cancer, and when anthracyclines are contraindicated.
Pulmonary complications are not commonly associated
with docetaxel or cyclophosphamide, and only a smallFigure 1 Computed tomography scans before (A), and (B) after the thnumber of cases have been reported in the literature
[4-21]. Here, we present the case of a patient receiv-
ing adjuvant TC who developed rapid-onset interstitial
pneumonitis, illustrating that no therapeutic interven-
tion is without its intrinsic and unanticipated risks.
Case presentation
A 72-year-old non-smoking Hispanic woman was initially
diagnosed as having a large right breast mass measuring
11×7×11cm on physical examination, and axillary adeno-
pathy. A core biopsy of the right breast and axillary lymph
nodes revealed infiltrating lobular breast carcinoma with
metastasis to the axilla. The tumor was both estrogen-
receptor and progesterone-receptor positive (ER+/PR+)
with Allred scores of 8 and 3, respectively. Immunostains
for human epidermal growth factor receptor 2 (HER2)/neu
were negative. Aside from the breast and axillary masses,
the remainder of her physical exam was unremarkable. A
subsequent staging bone scan and computed tomography
scan did not demonstrate any evidence of distant metasta-
ses, and she was therefore clinically staged as T3, N2 M0.
She was given pre-operative endocrine therapy with exe-
mestane (25mg) daily. Our patient tolerated exemestane
well with a clinical reduction in the size of the breast mass.
After approximately six months after starting exemestane,ird cycle of docetaxel/cyclophosphamide chemotherapy.
Figure 2 Photomicrographs of hematoxylin and eosin stain of lung wedge biopsy. (A) The lung interstitium is expanded by eosinophils
and edema. Pneumocyte hyperplasia is observed (×200, hematoxylin and eosin stain). (B) Hyperplastic pneumocytes showing pink and irregular
Mallory body-like inclusions (×400, hematoxylin and eosin stain).
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and axillary lymph node dissection. Histological examin-
ation revealed extensive tumor (ypT3ypN3) with 17 out of
20 lymph nodes involved with metastatic disease.
Due to the estimated 10-year risk of recurrence of ap-
proximately 80 percent, a decision was made to treat our
patient with adjuvant chemotherapy. Due to her age and
the increased risk of cardiac toxicity with anthracycline-
based chemotherapy regimens, our patient was treated
with TC chemotherapy (docetaxel 75mg/m2 and cyclo-
phosphamide 600mg/m2) once every three weeks for a
total of four planned cycles [3].
Our patient had no other medical problems prior to her
diagnosis of breast cancer aside from gastro-esophageal
reflux. Her surgical history, aside from the mastectomy
and lymph node dissection, included a prior appendec-
tomy for appendicitis and complete resection of a basal
cell carcinoma from her right leg. Our patient had no
known prior history of pulmonary or cardiac disease. She
worked as a phlebotomist, and there were no known occu-
pational exposures to industrial chemicals that would have
given her a greater risk of developing pulmonary disease.
Our patient had no major toxicities or issues related to
chemotherapy, aside from fatigue (grade 1 to 2) and
nausea and emesis (grade 2) with the first two cycles.Figure 3 Computed tomography scan approximately three months laHowever, approximately two weeks after receiving the
third cycle of chemotherapy, our patient developed rapidly
progressive dyspnea, and a non-productive cough, and
went to the emergency room at an outside medical facility.
She was found to have mild hypoxemia. A computed tom-
ography (CT) angiogram was performed, which was nega-
tive for evidence of a pulmonary embolus, but did reveal
the new onset of peripheral, subpleural fibrotic changes
not present on pre-treatment scans (Figure 1).
An attempt to pursue a needle lung biopsy at the outside
hospital was complicated by a pneumothorax that required
chest tube placement. Our patient was then transferred to
the University of Miami hospital, for a thorascopic-guided
wedge biopsy. Microscopic examination of the lung tissue
revealed subacute interstitial pneumonitis evolving into
areas of chronicity characterized by the presence of widen-
ing of alveolar septae with mild mononuclear infiltrates,
collections of eosinophils, and pneumocyte injury (Figure 2).
The latter was manifested by the presence of conspicuous
Mallory body-like inclusions in hyperplastic pneumocytes.
Areas of honeycombing were seen in the subpleural spaces.
There was no evidence of any associated malignancy. Our
patient was started on corticosteroids with rapid improve-
ment of her dyspnea. Approximately one month later after
her presentation to the emergency room, she no longerter showing improvement of interstitial pneumonitis.
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with exertion. Our patient was not given any additional
chemotherapy, and was then referred for post-mastectomy
radiotherapy. A CT scan performed approximately three
months later showed improvement of the previously seen
pulmonary infiltrates (Figure 3).
Discussion
We present the case of a woman who developed interstitial
pneumonitis (IP) after the third cycle of TC chemotherapy,
with no other identifiable risk factors. Using the key wordsTable 1 Summary of published cases in the English literature
pneumonitis
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cancer; TAC docetaxel, doxorubicin, cyclophosphamide; ThCD thiotepa, cyclophosph‘docetaxel’, ‘pneumonitis’ and ‘interstitial’ on PubMed identi-
fies 41 papers in English published in the last 15 years, of
which 17 represent reports of lung toxicity in patients re-
ceiving docetaxel: 15 specifically of pneumonitis and two
reports of bronchiolitis obliterans organizing pneumonia
[19,20]. In those 15 papers, there were a total of 48 cases,
with more than half of the cases having other lung comor-
bidities and no histological confirmation of the diagnosis
making the diagnosis of IP uncertain (Table 1).
The largest published series of docetaxel-related IP, was
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NSCLC treated with docetaxel (60mg/m2), that is, an
overall incidence of 4.6 percent [4]. However, 67 percent
of the patients that developed interstitial pneumonitis had
prior evidence of either chronic obstructive pulmonary
disease (COPD) or interstitial changes on CT scan, and
the diagnosis was not confirmed by biopsy. Therefore
other etiologies not related to chemotherapy, such as lym-
phangitic carcinomatosis, were not excluded. An explora-
tory analysis in this study identified a significantly
increased risk of interstitial pneumonitis in patients with
pre-existing radiographic evidence of emphysema (OR
4.95, P=0.016) or interstitial changes (OR 25.9, P<0.05).
The authors concluded that docetaxel should not be used
in patients with pre-existing interstitial changes on CT
scan, however only seven of 27 of such patients developed
pneumonitis, and therefore this recommendation should
be viewed with some skepticism especially in patients
where the overall therapeutic goal is curative and not pal-
liative. Histopathologic descriptions due to docetaxel-
related pulmonary toxicity are scant and lack details of the
findings. Among the cases with histological descriptions
and photomicrographs, they are limited to mentioning the
non-descriptive terms of interstitial pneumonitis/fibrosis.
Rare cases have shown tissue eosinophilia. Our patient
showed increased numbers of eosinophils, further sup-
porting the view of an exogenous injury such as drug tox-
icity as the cause of pneumonitis (Figure 2). Also, the
presence of Mallory-like bodies in pneumocytes indicates
that the damage at the cellular level was restricted primar-
ily to the epithelial lining of the alveoli [22].
In our review of previously published cases of docetaxel-
related interstitial pneumonitis, in most cases pneumonitis
occurred after two cycles, reported as early as after the
first cycle, and as late as after the ninth cycle. The overall
mortality rate from drug associated interstitial fibrosis esti-
mated from published case reports appears to be approxi-
mately 40 percent with 12 deaths in 30 cases where
mortality data was available (Table 1) [15].
However, pneumonitis is a well-established toxicity of
the alkylating agent cyclophosphamide [2]. The overall in-
cidence is unknown, but has been estimated to be less
than one percent of all patients who receive cyclophospha-
mide, with several confounding factors, including patients
concomitantly receiving other drugs known to cause
pneumonitis [2]. In a retrospective review from the Mayo
Clinic, 35 cases in a 20-year period were found with sus-
pected cyclophosphamide-induced interstitial pneumon-
itis, of which 29 were found to have other possible
etiologies [21]. Of the remaining six cases, one patient had
early-onset pneumonitis occurring approximately six
months after initiation of cyclophosphamide, while five
others developed late-onset pneumonitis, where three died
and in the other two patients follow-up information wasunavailable [21]. The same authors performed a retro-
spective review that revealed seven cases of early-onset
pneumonitis and five cases of late-onset pneumonitis with
a mortality rate of 29 percent in the early-onset cases, and
80 percent in the late-onset cases.
The incidence of interstitial pneumonitis in patients
receiving TC chemotherapy is unknown. It is highly
probable that it is a very rare complication, since thou-
sands of patients are treated each year with both agents
simultaneously, yet only a few scattered reports have
emerged in the literature. Since our patient received
both drugs, it is not possible to determine which agent
is responsible, but the clinical, radiological and histo-
logical findings strongly support the diagnosis of drug-
induced pneumonitis.
Conclusions
TC is commonly used as a safer alternative to anthracy-
clines in older patients with breast cancer, because of a
more favorable toxicity profile in comparison, but our
patient’s case illustrates that no chemotherapy is free of
risk, and that unanticipated serious complications, such
as interstitial pneumonitis, can occur [3]. Fortunately,
our patient made a rapid recovery and does not appear
to have suffered any permanent damage. Medical oncol-
ogists should be aware that while distinctly uncommon,
interstitial pneumonitis is a possible serious adverse tox-
icity associated with docetaxel/cyclophosphamide-based
chemotherapy.
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